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Abstract
Background: Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma
studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role of NK cells in
mediating rituximab-induced depletion of non-malignant B cells is unknown. The purpose of this study was to
provide fundamental data on rituximab-mediated effects on NK cells in PBMCs without tumor cells, in order to
simulate effects that could be relevant in patients with rheumatic disease.
Methods: Freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy donors were cultured overnight
with therapeutic antibodies. NK cells were isolated using a commercial kit or depleted from PBMCs using anti-CD56
and anti-CD16 monoclonal antibodies and magnetic beads. Cells were analyzed by multicolor flow cytometry.
Cytotoxicity assays were performed using 51Cr-labeled K562 target cells.
Results: Addition of rituximab to PBMCs resulted in depletion of B cells, which was dependent on NK cells and serum
factors. The extent of B cell depletion correlated with the percentage of NK cells. Following incubation with rituximab,
NK cells within PBMCs were activated, degranulated and downregulated the low affinitiy Fc-γ-receptor CD16 (FcγRIIIA).
The co-activating receptor CD137 (41BB) was upregulated on a fraction of NK cells. NK cell function was altered in
some donors in whom we observed rituximab-dependent reduction in NK cell cytotoxicity towards K562 tumor cells.
Conclusions: NK cells mediate rituximab-induced B cell depletion. Rituximab induces altered NK cell phenotype and
function.
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Background
Natural killer (NK) cells are tightly regulated lympho-
cytes with cytotoxic activity against stressed and/or
antibody-coated cells [1, 2]. The majority of human per-
ipheral blood NK cells are CD56dim NK cells bearing the
low affinity Fc-γ-receptor CD16 (FcγRIIIA). CD16 binds
IgG1 and mediates antibody-dependent cellular cytotox-
icity (ADCC) [3]. CD16 plays a prominent role in acti-
vating NK cells [4]. Following stimulation, NK cells
downregulate CD16 [5], by means of shedding [6] and
intracellular uptake [7]. CD137 (41BB) is a co-activating
receptor on NK cells that is upregulated upon binding of
certain antibodies to CD16 [8, 9], but a possible upregu-
lation upon binding of rituximab has not yet been
reported.
Rituximab is a chimeric antibody that targets CD20
present on healthy and malignant B cells, and mediates
depletion of these cells in vivo. It is used as a therapeutic
agent in a large range of malignant and autoimmune dis-
eases. Potentially, rituximab can trigger three effector
functions [10]: (1) programmed cell death, (2) induction
of complement-mediated cytotoxicity, and (3) ADCC
mediated by Fc-γ-receptor-bearing immune cells, includ-
ing CD16 on NK cells.
As shown in mouse models, Fc-γ-receptor-dependent
mechanisms contribute substantially to the action of
rituximab [11]. Clinical studies in humans confirm the
important role of CD16 and NK cells in rituximab-
mediated effects [12–17]. NK cells are activated in pa-
tients with lymphoma after rituximab infusion [18]. In
addition, in vitro studies describe specific interactions
between rituximab-coated (tumor) cells and NK cells
[19, 20]. These data establish that NK cells are important
mediators of rituximab-induced tumor cell lysis. In line
with this, combination of rituximab and other immuno-
therapies are newly explored to enhance NK cell cyto-
toxicity [21].
In rheumatology, rituximab has numerous on-label
and off-label applications, such as in rheumatoid arth-
ritis and granulomatosis with polyangiitis (GPA) [22]. In
these settings, elimination of autoimmune or over-
activated non-malignant B cells is believed to mediate its
therapeutic effect. Accordingly, rituximab is also referred
to as B cell therapy. Nevertheless, B cell depletion in
peripheral blood can be incomplete [23] and treatment
response frequently fails [24] or is incomplete or de-
layed. The reasons for this limited efficacy are unknown
and there are no predictors to identify patients who will
not benefit from rituximab.
Importantly, most studies investigating the mecha-
nisms of action of rituximab were performed in tumor
settings. Knowledge about rituximab-induced alterations
of NK cells in non-malignant contexts is very limited. One
study describes the modification of rituximab-induced
ADCC by recognition of additional tumor-specific NK cell
receptor ligands [19]. Therefore, the mechanisms of
rituximab-induced tumor cell lysis may not completely
apply for the elimination of non-malignant B cells, and
investigation of rituximab-mediated effects in non-
malignant settings is needed in order to better understand
and guide rituximab therapy in rheumatic disease.
Finally, we hypothesized that in addition to the
“primary” B cell depletion, rituximab could exert second-
ary effects on NK cells via Fc-CD16-interactions. In line
with this, Capuano et al. recently reported that pretreat-
ment with rituximab-coated tumor cells leads to general
inhibition of NK cell cytotoxicity [7]. It is not known
whether NK cells that have been exposed to rituximab
have altered functions in a non-malignant context.
The purpose of this study is to provide fundamental
data on rituximab-mediated effects on NK cells in
peripheral blood mononuclear cells (PBMCs) without
tumor cells, in order to simulate effects that could be
relevant in patients with rheumatic disease.
Methods
Donor consent and ethical approval
Informed consent was obtained from the healthy donors
before donation of blood. The ethics committee of the
University of Heidelberg approved this study.
PBMC and NK cell preparation
PBMCs were isolated by density gradient centrifugation
using Pancoll medium (PAN-Biotech GmbH, Aidenbach,
Germany) according to the manufacturer’s recommenda-
tions. PBMCs were used freshly whenever possible or
frozen on the day of blood donation. The anti-CD20
IgG1 antibody rituximab was used in saturated concen-
trations (10 μg/ml). Anti-tumor necrosis factor (TNF)
alpha monoclonal IgG1 antibody infliximab and intra-
venous immunoglobulins (IvIgs) were used as controls
(10 μg/ml). All three agents can theoretically bind CD16
and are used as therapeutic agents in rheumatic disease.
IvIg had been shown to induce phenotypical and func-
tional changes in NK cells when applied in high doses
(10 mg/ml) [25]. NK cells were isolated using the com-
mercial Dynabeads® Untouched™ Human NK Cell Kit
(ThermoFisherScientific/Life Technologies AS, Norway)
according to the manufacturer’s recommendations. NK
cells were depleted by incubation of freshly isolated
PBMCs with 5 μg/ml anti-CD56 (Clone MY31, Cat.
No 347740, BD Biosciences, San Jose, CA, USA) and
10 μg/ml LEAF™ purified anti-CD16 (Clone 3G8, Cat. No
302033, Biolegend, San Diego, CA, USA) for 20 minutes
on ice and subsequent magnetic separation using
Dynabeads® Pan Mouse IgG (ThermoFisherScientific/Life
Technologies AS, Norway) according to the manufac-
turer’s recommendations. Depletion controls are shown in
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Additional file 1: Figure S1a; NK cells were >90 % de-
pleted; CD56-positive T cells were reduced by this
procedure.
Flow cytometry
PBMCs were stained for 20–30 minutes on ice with a
cocktail of monoclonal antibodies, then washed and
directly analyzed on a four-laser flow cytometer (LSR
Fortessa, BD Biosciences, San Jose, CA, USA). Data were
processed using FlowJo® software (FlowJo LCC, Ashland,
OR, USA). The following antibodies were used: anti-
CD56 Brilliant Violet 421 (Clone NCAM16.2), anti-
CD54 PE, anti-CD19 FITC, anti-CD16 FITC (all from
BD Biosciences, San Jose, CA, USA); anti-CD3 PE-Daz-
zle, anti-CD69 PE, anti-CD137 PE (all from Biolegend,
San Diego, CA, USA). Where indicated, PBMCs were
washed and re-diluted for 20 minutes in Annexin-V
(AxV) buffer supplemented with Annexin-V PE before
analysis by flow cytometry.
Degranulation (CD107a) assays
Therapeutic antibodies and anti-CD107a PE-Cy5 (BD
Biosciences, San Jose, CA, USA) were added at the same
time point to freshly isolated PBMCs (1 × 106 cells/ml).
CD107a surface expression on NK cells was measured
after culture overnight by flow cytometry as described.
Cytotoxicity assays
The target cell line K562 was grown in medium (IMDM,
10 % FCS, 1 % penicillin/streptomycin) to mid-log phase:
5 × 105 target cells were labeled in 100 μl assay medium
(IMDM with 10 % FCS and penicillin/streptomycin) with
100 μCi of 51Cr for 1 to 2 hours at 37 °C. Cells were
washed twice in assay medium and resuspended at 5 ×
104 cells/ml in assay medium. Five thousand target cells/
well were used in the assay. Effector cells (freshly iso-
lated PBMCs) were resuspended in assay medium and
mixed with labeled target cells in a V-bottom 96-well
plate. Maximum release was determined by incubation
in 1 % Triton X-100. For spontaneous release, target
cells were incubated without effector cells in assay
medium alone. All samples were done in triplicates.
Plates were incubated for 4 hours at 37 °C. Supernatant
was harvested, and 51Cr release was measured in a
gamma counter. Percentage of specific release was calcu-
lated as:
ð Experimental release – Spontaneous releaseð Þ
 Maximum release – Spontaneous releaseð ÞÞ  100:
Statistical analysis
Exploratory statistical analysis was performed. P values
have to be interpreted descriptively. Normal distribution
was not assumed and therefore non-parametric statis-
tical tests were used. The Mann–Whitney test was used
to compare two groups. The Wilcoxon signed rank test
was used to compare paired samples. All tests were
performed with a significance level of 5 % (confidence
interval 95 %).
Results
Addition of rituximab to PMBCs leads to B cell depletion
in the absence of serum
Freshly isolated PBMCs from 14 healthy donors were
cultured with or without rituximab overnight. In all do-
nors we observed a strong rituximab-mediated reduction
in B cell numbers, and no B cells were detectable after
rituximab treatment (<0.55 % of lymphocytes) in 10/14
donors (Fig. 1a). In the first experiments, we used anti-
TNF alpha antibody infliximab or IvIgs as negative con-
trols. We discontinued these controls in further experi-
ments, as no effects on either the presence of B cells
(Fig. 1a; infliximab, n = 2; IvIg, n = 1) nor the degree of
NK cell degranulation was seen (see subsequent text;
infliximab, n = 3; IvIg, n = 2). Infliximab had no effect on
B cell proportions, even after culture over 4 days and
contrary to rituximab (n = 2, not shown). B cell depletion
was incomplete in 4/14 donors following rituximab
treatment overnight (Fig. 1b, c). The expression of CD19
on the remaining B cells was decreased and viability
staining with Annexin V revealed that an important frac-
tion of these cells was apoptotic (Fig. 1b). Donors with
incomplete B cell depletion had a significantly lower ra-
tio of NK cells to B cells at baseline than donors with
complete B cell depletion (Fig. 1c).
These data indicate that rituximab can induce B cell
depletion in PBMCs without the presence of functional
serum factors. Low ratios of NK cells to B cells might be
responsible for incomplete, presumably delayed, B cell
depletion.
Rituximab leads to NK cell degranulation and
downregulation of CD16 in PBMCs
The degranulation of NK cells was measured in six do-
nors after culture of freshly isolated PBMCs with or
without rituximab (or control antibody infliximab, n = 3,
and IvIg, n = 2) overnight. CD107a expression as a cor-
relate of degranulation was increased only if rituximab
had been added (Fig. 2a, b). In the six donors investi-
gated, CD107a expression was statistically significantly
higher in samples that contained rituximab than in sam-
ples that contained no therapeutic antibody (Wilcoxon
signed rank test, p = 0.03; not shown).
The Fc-gamma-receptor CD16 was downregulated on
degranulated (CD107a-positive) NK cells, as shown in
Fig. 2c. The proportion of CD16bright cells among
CD56dim NK cells was determined after culture with or
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Fig. 1 Addition of rituximab to peripheral blood mononuclear cells (PMBCs) leads to B cell depletion in the absence of serum. a PBMCs were
isolated by density gradient centrifugation, left untreated overnight, and cultured over the second night in medium supplemented with heat-
inactivated fetal calf serum without any therapeutic antibody (w/o, left panel), with 10 μg/ml anti-CD20 antibody rituximab (RTX) (middle) or with
10 μg/ml anti-TNF alpha antibody infliximab (right panel). After that, PBMCs were stained with a mixture of lineage antibodies (anti-CD3 PE-
Dazzle, anti-CD56 Bv421, anti-CD19 FITC) and analyzed by flow cytometry. B cells were identified as CD3-CD19+ cells in the lymphocyte gate. b
PBMCs were treated as described (a). After washing PBMCs were re-diluted in Annexin-V (AxV) buffer supplemented with PE-labeled Annexin-V
and analyzed by flow cytometry. B cells were identified as CD3-CD19+ cells in the lymphocyte gate. Upper row culture in medium without RTX
(w/o RTX). Lower row culture in medium with RTX (+ RTX). AxV+ B cells apoptotic B cells with positive staining for Annexin-V PE. a, b B cell
numbers were reduced after incubation with RTX in 14/14 independent experiments, each performed with PBMCs from different healthy
donors. In 10/14 experiments RTX-induced B cell depletion was complete as shown (a); in 4/14 B cell depletion was incomplete as shown (b).
Infliximab was used as a negative control in 2/14 experiments. Increased binding of Annexin-V was identified in three donors with incomplete
B cell depletion. c Left graph B cell percentages before and after culture overnight with rituximab (statistically significant, Wilcoxon signed rank
test, p = 0.001). Right graph, whiskers 10–90th percentile. PBMCs with incomplete B cell depletion after incubation with RTX overnight
(incomplete) had significantly lower ratios of natural killer cells to B cells (NK/B) than PBMCSs with complete B cell depletion (complete, <0.55 % of
PBMCs) (Mann–Whitney U test, p = 0.03)
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without rituximab in 16 healthy controls. Rituximab led to
a significant decrease in CD16bright NK cells (Fig. 2d). The
extent of CD16 downregulation varied between donors.
We conclude that rituximab induces NK cell degranu-
lation in healthy PBMCs. Similar to published data in
tumor models, rituximab induced downregulation of
CD16.
NK cells and serum cooperate in mediating rituximab-
induced B cell depletion
To investigate a causal relationship between NK cell de-
granulation and the depletion of B cells upon rituximab
treatment we depleted NK cells from freshly isolated
PBMCs using anti-CD56 and anti-CD16 antibodies and
magnetic beads. The remaining PBMCs were cultured
overnight with or without rituximab and with or without
autologous human serum.
Rituximab-induced B cell depletion was abrogated if
NK cells were depleted from the PBMCs (Fig. 3a, n = 4
donors). However, the addition of active autologous hu-
man serum in addition to rituximab led to reduced
numbers of B cells in NK-depleted PBMCs (Fig. 3b,
n = 4). This effect was abrogated if the serum was
heat inactivated, or if serum was not added (Fig. 3b).
The greatest reduction in B cells was in samples con-
taining both NK cells and active serum (Fig. 3c). The
complete experiment with all negative controls, in-
cluding the proof of successful NK cell depletion is
shown in Additional file 1: Figure S1(a).
These data demonstrate that in the absence of serum,
NK cells are responsible for rituximab-induced B cell de-
pletion. In the absence of NK cells, serum factors such
as complement alone can mediate rituximab-induced B
cell reduction and NK cells and serum factors have a
complementary effect on rituximab-induced B cell
reduction.
The extent of rituximab-induced B cell depletion
correlates with the size of NK cell proportions
To investigate the correlation between the amount of B
cell depletion and the ratio of NK to B cells (Fig. 1), we
resubstituted NK-cell-depleted PBMCs with autologous
NK cells from three different healthy donors (Fig. 4a, b,
and c, respectively). The addition of increasing amounts
of NK cells led to increasingly profound decrease in B
cells (Fig. 4, gray bars). This decrease was not an indirect
consequence of increased NK cell proportions, as
shown by the negative control samples cultured without
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Fig. 2 Rituximab (RTX) leads to natural killer (NK) cell degranulation and downregulation of CD16 in peripheral blood mononuclear cells (PBMCs).
PBMCs were isolated and cultured as described in Fig. 1. Anti-CD107a PE-Cy5 was added at the same time point as the therapeutic antibodies
(starting point of the degranulation assay). The next day PBMCs were stained with a mixture of antibodies (anti-CD3 PE, anti-CD56 Bv421 and
anti-CD16 FITC) and analyzed by flow cytometry. NK cells were identified as CD3-CD56+ cells in the lymphocyte gate. a CD107a expression on
CD56dim NK cells after stimulation without (w/o) therapeutic antibody, with 10 μg/ml RTX (+RTX), with 10 μg/ml infliximab and with 10 μg/ml
intravenous immunoglobulin (IvIg) (from left to right). Shown is one representative donor. b Summary of the increased CD107a expression on total
NK cells after treatment with RTX in comparison to infliximab. Dots linked by a line belong to the same donor. Additive effect on degranulation is
defined by (CD107a pos. NK cells after culture with therapeutic antibody) -(CD107a pos. NK cells after culture without therapeutic antibody).
c CD16 expression on CD107a-positive NK cells. Shown is one representative donor. a-c CD107a expression together with CD16 expression has
been investigated in healthy individuals (n = 6 (+/− RTX), n = 3 (+/− infliximab) and n = 2 (+/− IvIg)). d The percentage of CD16bright cells among
CD56dim NK cells before and after stimulation with RTX overnight was investigated in 16 healthy donors. Statistical significance was determined
with the Wilcoxon signed rank test (p = 0.0005). FSC forward scatter
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Fig. 3 Natural killer (NK) cells and serum cooperate in mediating rituximab (RTX)-induced B cell depletion. NK cells from freshly isolated peripheral
blood mononuclear cells (PBMCs) were depleted (or not) using anti-CD56 and anti-CD16 antibodies and magnetic beads as described in
“Methods”. The remaining PBMCs were cultured overnight with (+) or without (w/o) RTX and with or without autologous human serum. HI heat
inactivated. The next day PBMCs were stained and analyzed as described in Fig. 1. a All samples were cultured without human serum. b NK cells
were depleted in all samples. c All samples were treated with RTX over night. a-c Data from the same experiment and donor with incomplete NK
cell depletion; the complete experiment with all negative controls including proof of successful NK cell depletion is shown in Additional file 1:
Figure S1(a). The effect of NK cell (depletion) and serum on the extent of the B cell depletion and failed RTX-induced B cell depletion in samples
without serum and without NK cells were seen in four independent experiments with four different donors
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rituximab (Fig. 4, black bars). One complete experiment
with all combination scenarios (+/− rituximab, +/− NK
cell depletion, +/− NK cell re-substitution) is shown in
Additional file 1: Figure S1(b).
In order to statistically analyze this effect, the ratio
(B cells (% of lymphocytes) in samples treated with ri-
tuximab)/(B cells in samples treated without rituximab)
was calculated and related to the respective NK cell
percentages (% of lymphocytes). The linear regression
analysis of the donor shown in Fig. 4a was significant
(R2 = 0.9993, p = 0.0003), whereas the analysis of the do-
nors shown in Fig. 4b and c were not significant (most
likely due to limited measurements per donor). The
pooled correlation analysis was significant (Spearman's
r = −0.736, p = 0.0047). We conclude that B cell depletion
can be accelerated by elevated NK cell proportions.
Rituximab leads to further phenotypic changes in CD56dim
NK-cells
We investigated the expression of the lymphocyte activa-
tion marker CD69 on CD56dim NK cells from freshly
isolated PBMCs from 13 healthy donors. After culture
with rituximab overnight, CD69 expression was statisti-
cally significantly greater than after culture without ri-
tuximab (Wilcoxon signed rank test, p = 0.0002; Fig. 5a).
A median of 25 % of CD56dim NK cells expressed CD69
de novo.
Using the same culture conditions, the expression
levels of the NK cell co-activation receptor CD137
(41BB) was investigated in 11 donors (Fig. 5b). Rituxi-
mab significantly increased the expression of CD137
(p = 0.001). A median of about 10 % of CD56dim NK
cells expressed CD137 as a response to rituximab.
Therefore, next to the effects of rituximab that can be
directly assigned to Fc-γ-receptor CD16 signaling (such
as degranulation and downregulation of CD16), an im-
portant fraction of CD56dim NK cells showed unspecific
signs of activation and the expression of at least one co-
activating receptor was altered.
NK cells exposed to rituximab can become hypo-
responsive in a donor-dependent fashion
We hypothesized that the phenotypic changes described
might impact the NK cell cytotoxicity towards other
target cells. To explore this, we performed a series of
killing assays with 11 healthy donors. Freshly isolated
PBMCs were cultured overnight with or without rituxi-
mab, washed, and then co-cultured for 4 hours with the
NK cell-sensitive, 51Cr-labeled K562 cell line. Lysis of
K562 cells by NK cells is independent of Fc-receptors.
We observed donor-dependent effects of rituximab on
NK cell cytotoxicity. While many donors had no reduc-
tion or only slight reduction in cytotoxicity after culture
with rituximab (Fig. 6a) we observed statistically signifi-
cant reduction in NK cell cytotoxicity upon rituximab
pretreatment in three donors (Fig. 6b). Due to this donor
variability, on statistical analysis of the overall NK cell
cytotoxicity in all donors there was a non-significant
trend towards reduced NK cell cytotoxicity upon culture
with rituximab (Fig. 6c).
These data indicate that incubation of non-malignant
PBMCs with rituximab alters NK cell cytotoxicity in a
donor-dependent fashion.
Discussion
Anti-CD20 tumor therapy with rituximab has broad ap-
plications in hematology. Many studies confirm its
clinical and mechanistic effects, and NK cells are a well-
described mediator of rituximab-induced tumor lysis
[21]. The progress in understanding rituximab-induced
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Fig. 4 The extent of rituximab-induced B cell depletion correlates with the size of natural killer (NK) cell proportions. NK cells were isolated from
one fraction of freshly isolated peripheral blood mononuclear cells (PBMCs) and left untreated overnight. Another fraction of freshly isolated
PBMCs was left untreated overnight and NK cells were depleted the next day using anti-CD56 and anti-CD16 monoclonal antibodies and magnetic
beads. NK-cell-depleted PBMCs were resubstituted with isolated NK cells in three different proportions. The samples were incubated with (gray bars) or
without (black bars) 10 μg/ml rituximab overnight. PBMCs were stained and analyzed by flow cytometry as described in Fig. 1. a-c Three independent
experiments. First bars show NK cell depletion without re-substitution. Second to fourth bars show NK cell depletion with resubstitution of different
percentages of NK cells as indicated. a Data from the same experiment shown in Fig. 3 (cultured without human serum); the complete experiment
with all negative controls including proof of successful NK cell depletion is shown in Additional file 1: Figure S1(b). b, c Two further experiments
performed with different donors (cultured with autologous human serum). The statistical analysis is described in “Results”
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NK cell-mediated effects has recently been highlighted
by the finding that NK cells are less cytotoxic after co-
culture with rituximab-coated tumor cells [7]. Indeed,
multiple activating pathways are blocked through inter-
nalized CD16 that atypically binds the phosphatase
SHP1, which in turn leads to the disruption of central
steps of NK cell activation [7]. This finding is of the up-
most importance in lymphoma therapy. Lymphomas
often consist of CD20-positive and CD20-negative trans-
formed B cells: although CD20-positive cells could be
successfully defeated with rituximab, the CD20-negative
fraction could be less successfully suppressed by NK
cells with reduced cytotoxicity, and grow out, leading to
rituximab resistance and a worse outcome. Apart from
the findings discussed subsequently, the present study is
the first to confirm inhibited NK cell cytotoxicity after
pretreatment with rituximab in a non-malignant experi-
mental setting.
Rituximab also has broad and increasing applications
in rheumatology. However, there is a lack of mechanistic
studies. Although B cell therapy is believed to be central
in mediating the anti-inflammatory effect of rituximab,
several clinical findings cannot be explained by it or
seem to be contradictory. For example, despite the initial
idea that depletion of B cells would diminish pathogenic
autoantibodies, elevated serum levels of autoantibodies
do not strictly correlate with clinical response [26], and
can persist despite effective rituximab treatment. Vice
versa, treatment response can fail, even with successful
B cell depletion. Essentially and due to the absence of
biomarkers, it remains unclear, which patients would
benefit from rituximab and which would be unrespon-
sive to it.
The transfer of knowledge from cancer studies to
rheumatic disease might be erratic because of secondary
effects intrinsic to tumor cells [19]. Therefore, studies of
rituximab under non-malignant conditions are needed
to identify the precise conditions that are required for
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Fig. 5 Rituximab (RTX) leads to further phenotypical changes in
CD56dim natural killer (NK) cells. Freshly isolated peripheral blood
mononuclear cells (PBMCs) were incubated with (+) or without (w/o)
RTX overnight. The next day PBMCs were stained with a mixture of
antibodies (anti-CD3 PE-Dazzle, anti-CD56 Bv421 and anti-CD16 FITC
and CD69/CD137 PE) and analyzed by flow cytometry. NK cells were
identified as CD3-CD56+ cells in the lymphocyte gate and fluorescence
intensity of PE on CD56dim NK cells was measured. a CD69 PE. Histo-
gram shows one representative donor; gray incubation + RTX, black w/
o RTX. Left diagram mean CD69 PE fluorescence intensity in samples
from 13 donors. Statistical significance was determined with the
Wilcoxon signed rank test (p = 0.0002). Right diagram Δ % in
CD56dim NK was determined by (CD69-positive CD56dim NK cells after
incubation + RTX) - (CD69-positive CD56dim NK cells after incubation
w/o RTX); bar median. b CD137(41BB)-PE; same donor, layout and ab-
breviations as in a; n = 11 donors; p = 0.001
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successful treatment of rheumatic diseases with rituxi-
mab, and to understand the previously mentioned clin-
ical discrepancies. The present study was supposed to
provide a fundamental “health condition” basis for fur-
ther studies on the interactions between rituximab and
NK cells in rheumatic disease.
Our first major finding is the participation of NK cells
in mediating rituximab-induced B cell depletion in our
non-malignant experimental setting. This finding is sup-
ported by the association between incomplete or delayed
B cell depletion and a low ratio of NK cells to B cells, by
the specifically increased degranulation and the down-
regulation of CD16, by the absence of B cell depletion in
the case of concomitant NK cell depletion (and missing
serum factors), by the correlation between the extent of
B cell reduction and the amount of re-substituted NK
cells and finally, by distinct phenotypic changes in
rituximab-treated samples.
NK cells and serum (presumably complement) factors
seem to synergize. This is interesting, as both parame-
ters can be deficient in diverse clinical situations. It
would be interesting to investigate whether NK cells play
a more prominent role in hypocomplementemia, e.g. in
active systemic lupus erythematosus; or whether
complement-dependent effects are more pronounced in
situations where NK cell numbers are reduced, e.g. in
highly active GPA (own data, publication in preparation).
The two parameters might also be differently relevant
depending on the location. NK cells are not detectable
in GPA granulomas [27], but B cells are present [28].
Herein may lay the reason for the limited efficacy of ri-
tuximab in treating granulomatous lesions, and why B
cells can be found in granulomas despite complete de-
pletion in peripheral blood [29]. In any case, NK cells
are mediators of rituximab-induced B cell depletion in a
non-malignant setting. We suggest that NK cell propor-
tions in peripheral blood and tissue lesions should be
systematically investigated in rheumatic disease in the
context of rituximab therapy.
Direct apoptotic effects of rituximab or ADCC by
monocytes do not seem to be relevant in our setup. In
line with this, in PBMCs NK cells, but not monocytes,
have been found to mediate cytotoxicity towards
rituximab-coated tumor cells [30]. However, a marginal
direct apoptotic effect might not be completely excluded
and could explain the slight shift in the B cell population
from Fig. 3a (left and right graph).
The second major finding of the present study is the
altered NK cell function after pretreatment with rituxi-
mab. It must be noted that the only other study that de-
scribed NK cell inhibition by rituximab was performed
using large amounts of rituximab-coated tumor cell line
cells [7]. Thus, this study investigated rituximab-induced
NK cell changes after a maximum of a stimulus. Our ex-
perimental ex vivo setting, on the contrary, operates in
the most physiological fashion by using PBMCs. Essen-
tially, the ratios of NK cells to target cells (B cells) were
unaltered, and effects on NK cells are likely to be trans-
ferable in vivo. Therefore, it would be interesting to in-
vestigate whether the inhibited NK cell cytotoxicity
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Fig. 6 Natural killer (NK) cells exposed to rituximab (RTX) can
become hypo-responsive in a donor-dependent fashion. Freshly
isolated peripheral blood mononuclear cells (PBMCs) from 11 healthy
donors were cultured overnight with or without (w/o) RTX in
medium without human serum. After washing, PBMCs (effector cells
(E)) and 51Cr-labeled K562 (target (T)) cells were co-cultured for
4 hours. Percent specific lysis was determined by measuring 51Cr in
the supernatant. For every donor a ratio of the % specific lysis with
and without RTX ((RTX)/(w/o RTX)) was calculated for each E/T and
statistically analyzed by comparison with a hypothetic mean value of
1 using the one-sample t test. a Although eight donors had no
significant changes in NK cell cytotoxicity (b) we observed that RTX
significantly inhibited NK cell cytotoxicity in three donors (p < 0.05).
c To compare all donors, we calculated the area under the curve
(AUC) for each cytotoxicity assay with and without RTX pretreatment.
Shown is log10 (AUC with RTX)/(AUC w/o RTX). Data were analyzed
using the one-sample t test (not significant, p = 0.0593; bar mean)
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might be relevant in the treatment of patients with non-
malignant disease.
This raises the question about a possible consequence
of decreased NK cell cytotoxicity in rheumatic diseases.
We can only speculate about this. Decreased NK cell
cytotoxicity by rituximab could lead to a clinical benefit
if NK cells are pathogenic, e.g. hyperactive in a given
disease. On the other hand, it could have a detrimental
effect if NK cells have a protective role. So far, the in-
volvement of the function of NK cells is not established
in most rheumatic diseases, but they could play a role,
e.g. in Sjögren’s syndrome or GPA [27, 31].
We could not make up differences between donors
with decreased and unaltered cytotoxicity after treat-
ment with rituximab. The ratio of NK cells to B cells
and loss of CD16bright cells were not different between
the groups (not shown), but the subgroups were too
small to draw any conclusions. The factors causing de-
creased cytotoxicity after rituximab-treatment remain
unknown. Possible reasons could comprise CD16 poly-
morphisms with different affinity to rituximab, counter-
regulation by unknown factors (see also subsequent
text), time dependence and sensitivity of our experimen-
tal setup, or others. Clinical trials should investigate
whether there is correlation between altered NK cell
cytotoxicity and response to rituximab treatment.
To summarize, these data show that rituximab induces
altered NK cell phenotype and function, and the clinical
significance of this needs to be established. These data
are fundamental in understanding how rituximab works
in non-malignant diseases, and will lead to further stud-
ies investigating the role of NK cells and rituximab in
rheumatic diseases.
Another important finding is the upregulation of the
co-activating receptor CD137 (41BB) on a subset of
CD56dim NK cells. This finding is precious, as all other
activating receptors investigated so far are not altered
after rituximab pretreatment (NKG2D, 2B4, NKp46,
NKp30, DNAM1, LFA1 and CD2-receptor) [7]. Upregu-
lation of this receptor could be a reason why the reduc-
tion of NK cell cytotoxicity is relatively weak, as the
tumor cell line K562 expresses small amounts of CD137
ligand (CD137L, 41BBL, not shown). Therefore, the re-
sults from Fig. 6 could underestimate the extent of the
reduction in killing, depending on the nature of a given
target cell. The finding of upregulation of CD137 could
be of clinical importance, as agonist anti-CD137 anti-
bodies are tested for clinical use [21]. The idea is to
combine a tumor binding antibody with agonist anti-
CD137 antibody in order to enhance NK cell cytotox-
icity towards tumor cells [8, 32]. We suggest that such a
combination might also be applicable in rheumatic dis-
ease, e.g. in patients with incomplete B cell depletion or
response to rituximab. Furthermore, anti-CD137 can be
used to enhance NK cell proliferation in vitro [33, 34],
and NK cell numbers had been shown to be inversely
correlated with GPA activity [27]. It would be interesting
to test agonist anti-CD137 antibody in combination with
rituximab in rheumatic diseases.
Conclusions
In summary, we show that NK cells mediate rituximab-
induced B cell depletion in a non-malignant experimen-
tal setting. Rituximab induces altered NK cell phenotype
and function, for which the clinical significance needs to
be investigated.
Additional file
Additional file 1: Figure S1a. NK cells and serum cooperate in mediating
rituximab-induced B cell depletion. Same experiment as shown in Fig. 3; all
samples and controls are shown. -/+ RTX, without/with rituximab. Figure
S1b. The extent of rituximab-induced B cell depletion correlates with the size
of NK cell proportions. Same experiment as shown in Fig. 4a; the complete
experiment with all negative controls including proof of successfull NK cell
depletion is shown. -/+ RTX, without/with rituximab. (ZIP 421 kb)
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